Oncology has seen extraordinary breakthroughs in AI, data science, and computational biology, yet in the clinic, cancer care remains largely protocol-driven. That’s not because the industry hasn’t innovated. It’s because the foundation of modern cancer medicine was built to do one thing extremely well: treat the average patient.
Protocols exist because they are the statistically safest way to practice medicine when certainty is impossible. They are built on decades of clinical trials, real-world outcomes, and population-level evidence. In many areas of healthcare, that system works remarkably well. But cancer exposes its limits.
Cancer Care Is Still Running on Averages. That Era Is Ending.
Cancer care has evolved the same way large language models (LLMs) evolve: by gatheringmassive historical datasets, identifying patterns, and producing the statistically “best” next step. It’s an impressive machine. But it has a ceiling. Cancer isn’t text. Patients aren’t averages. Two people with the same diagnosis, and even the same mutations, can respond in completely different ways.
That is the uncomfortable truth oncology keeps running into: even the most advanced predictive models cannot fully capture the lived biology of an individual patient. Tumors adapt. Pathways compensate. Microenvironments shift. Resistance emerges. The reality inside one patient’s body may not match what worked best for 10,000 patients before them.
So, oncology remains protocol-driven because the alternatives have historically been too slow, too manual, too inconsistent, or too expensive to use at scale. Until recently, there wasn’t a practical way to replace population averages with individualized biological evidence.
That’s why the next era isn’t just about better prediction. It’s about a new foundation, where we stop guessing based on the past and start measuring truth in the present.
AI-Enabled Functional Testing Exposes the Drawbacks of Genomics-Only and Population-Based Cancer Care
The rise of AI-enabled functional testing reveals something oncology has quietly known for years: prediction-only medicine isn’t enough.
Genomics has been a revolution. It helped us classify cancers more precisely, identify targets, and build therapies that changed outcomes for many patients. But genomics is not the full story; it’s just one layer of the story. It tells you what mutations are present. It doesn’t always tell you what those mutations do in a living tumor under real-world conditions, inside a patient with their own biology, history, and treatment exposure.
Cancer isn’t a static blueprint. It’s a living system. It rewires. It adapts. It survives. And that’s why two patients can share the same mutation yet respond completely differently to the same drug. Genomics can’t always see resistance mechanisms, pathway redundancy, microenvironment effects, immune suppression, or drug sensitivity that only show up when you test the tumor itself.
Population-based models have similar limitations. They are designed to answer: what works best for most people? But the patient in front of the doctor isn’t “most people.” They are one individual. And when cancer becomes aggressive, relapsed, or rare, averages become less useful, and trial-and-error becomes the default.
This is where functional precision medicine (FPM) becomes an inflection point. Instead of relying solely on what should work based on prior datasets, FPM measures what does work by testing hundreds of FDA-approved therapies directly on a patient’s living tumor cells. The patient becomes their own control. The data becomes real. The answer becomes personal.
AI doesn’t replace biology here; it unlocks it. It helps interpret complex response landscapes and turn functional results into clear, actionable decisions at clinical speed.
How Robotics, Automation, and AI Make Functional Precision Medicine (FPM) Fast & Clinically Accurate
Functional precision medicine (FPM) only changes cancer care if it can deliver answers fast enough to matter, and consistently enough to trust. That’s why the real breakthrough is not just functional testing itself, but the platform behind it: biology, automation, robotics, and AI working together as a single system.
Cancer doesn’t wait. When a patient’s disease is progressing, every day matters. Traditional experimentation in biology is slow, manual, and fragile. It doesn’t scale. It varies from lab to lab, person to person, and even day to day. That level of variability is unacceptable when decisions impact real lives.
• Robotics: Advanced cell enrichment technology combined with robotics replaces slow, error-prone manual work with fast, consistent, high-throughput testing of hundreds of FDA-approved therapies and combinations on a patient’s living tumor cells—delivering precision and repeatability at clinical speed. Robotics removes the inconsistency of manual pipetting and reduces variability that can distort results. It turns complex biology into a repeatable process.
• Automation: Automation adds speed and reliability. It compresses workflow time by standardizing processes, reducing bottlenecks, and maintaining consistent conditions. It’s what allows a platform to deliver answers in days instead of weeks—so results arrive while the patient can still benefit.
• Artificial Intelligence (AI): AI turns complexity into clarity. Functional testing generates thousands of patient-specific data points, response curves, sensitivity patterns, resistance signals, and combination effects. AI can rapidly analyze those patterns, rank therapies, and translate raw biology into actionable insights that a physician can use with confidence.
This is how personalization stops being a buzzword and becomes a clinical reality: fast, reproducible, and specific to the individual. Not probability. Not averages. Not “most patients.” Just experimentally validated truth for this patient, delivered at the speed cancer demands.
AI Moves Oncology Toward Experimentally Validated, Patient-specific Insights
AI has transformed what we can predict in medicine. But prediction is still not the same thing as truth, and cancer is where that distinction matters most.
Most AI in oncology today is trained the same way modern LLMs are trained: massive datasets, historical outcomes, and statistical pattern recognition. These models can generate impressive probabilities, response likelihoods, risk scores, survival curves, and “best next treatments.” But they are still making educated guesses based on what happened to other people.
That approach has powered progress, but it has a ceiling. Cancer isn’t language. Biology is not interchangeable. A patient isn’t an average. Even the best model can’t fully predict how a living tumor will respond inside a specific human body, shaped by unique biology, previous treatments, and evolving disease.
This is where functional precision medicine changes everything. Instead of asking AI to guess what should work, we give AI real patient-specific evidence to interpret. When a patient’s live tumor cells are tested against hundreds of FDA-approved therapies, we generate something oncology rarely gets: experimentally validated truth.
Now AI can do what it’s best at, detecting patterns, ranking options, interpreting complex multidimensional data, without pretending population averages apply to one individual. AI becomes the accelerator of truth, not the generator of assumptions.
That’s the shift from probabilistic medicine to experimentally grounded medicine. Not AI replacing doctors. Not AI replacing biology. But AI working with biology, measuring how the cancer actually behaves, and turning that behavior into actionable insights where the doctor uses that information to make data-informed decisions.
This is not science fiction. It’s happening right now. Patients are being treated. Lives are being saved today. The future of oncology will belong to platforms that stop guessing and start measuring, then use AI to scale it to every patient.
Cancer care is still running on averages, but that era is ending. The tools exist today to move beyond probability and into proof. The next leap in oncology won’t come from one magical algorithm. It will come from biology, technology, and AI working in harmony at the individual level, so every patient becomes their own source of truth.
